-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation